Supercharged donor cells take on viruses after transplant
NCT ID NCT02048332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boost the patient's weakened immune system using cells from their donor, potentially reducing hospital stays and side effects from medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akron Children's Hospital
RECRUITINGAkron, Ohio, 44308, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
University of Cincinnati Medical Center
COMPLETEDCincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can a new IV antiviral tame two stubborn viruses?
- Can specially grown immune cells from donors beat viruses that won't go away?
- A new drug combo may shield kidney transplant patients from a common viral threat
- Blood test could tailor CMV prevention after stem cell transplants
- Scientists compare immune responses to viral and bacterial infections in ICU patients